L. Cheung

发表

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer

M. Schiffman, P. Castle, T. Lorey, 2018, Annals of Internal Medicine.

FLEXIBLE RISK PREDICTION MODELS FOR LEFT OR INTERVAL-CENSORED DATA FROM ELECTRONIC HEALTH RECORDS.

M. Schiffman, H. Katki, L. Cheung, 2017, The annals of applied statistics.

Life-GainedBased Versus Risk-Based Selection of Smokers for Lung Cancer Screening

C. Berg, P. Castle, A. Chaturvedi, 2019, Annals of Internal Medicine.

Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States

C. Berg, A. Chaturvedi, H. Katki, 2019, Annals of Internal Medicine.

Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 20052015

A. Jemal, C. Berg, A. Chaturvedi, 2018, Annals of Internal Medicine.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

M. Schiffman, P. Castle, T. Raine-Bennett, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of Cervical Precancer and Cancer Among Uninsured and Underserved Women 2009-2017.

M. Schiffman, N. Wentzensen, M. Saraiya, 2020, American journal of obstetrics and gynecology.

2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation

M. Schiffman, N. Wentzensen, H. Katki, 2020, Journal of lower genital tract disease.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2017, Journal of lower genital tract disease.

OP-JNCI200215 1590..1594

C. Berg, A. Chaturvedi, H. Katki, 2021 .

OP-JNCI190046 996..999

C. Berg, A. Chaturvedi, H. Katki, 2019 .

The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics

Nicole E. Varnado, N. Wentzensen, P. Castle, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

M. Schiffman, P. Castle, T. Lorey, 2017, Preventive medicine.

Adherence Patterns to Extended Cervical Screening Intervals in Women Undergoing HPV and Cytology Cotesting

M. Schiffman, P. Castle, T. Lorey, 2017 .

Why does cervical cancer occur in a state-of-the-art screening program?

M. Schiffman, P. Castle, T. Lorey, 2017, Gynecologic oncology.

Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2020, Journal of lower genital tract disease.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Mark Schiffman, Sholom Wacholder, Hormuzd A Katki, 2011, The Lancet. Oncology.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years

M. Schiffman, P. Castle, T. Lorey, 2018, Cancer Prevention Research.

A joint model of persistent human papilloma virus infection and cervical cancer risk: implications for cervical cancer screening

P. Castle, H. Katki, R. Sundaram, 2015, Journal of the Royal Statistical Society. Series A,.

Premature conclusions on HPV-only testing – Authors' reply

S. Wacholder, M. Schiffman, P. Castle, 2011 .

Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005–2015

Ahmedin Jemal, Hormuzd A. Katki, Anil K. Chaturvedi, 2018 .

A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs

M. Schiffman, P. Castle, T. Raine-Bennett, 2020, EClinicalMedicine.

Risk-Based Selection of Individuals for Oral Cancer Screening.

B. Graubard, A. Chaturvedi, H. Katki, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial

C. Berg, H. Katki, R. Landy, 2019 .

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy

M. Schiffman, N. Wentzensen, P. Castle, 2018, Journal of lower genital tract disease.

Different human papillomavirus types share early natural history transitions in immunocompetent women

P. Castle, A. Rodriguez, M. Schiffman, 2022, International journal of cancer.

Variation in Human Papillomavirus Vaccination Effectiveness in the US by Age at Vaccination

A. Chaturvedi, H. Katki, R. Landy, 2022, JAMA network open.

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Diane Solomon, Allan Hildesheim, Sholom Wacholder, 2010, Journal of the National Cancer Institute.

Risk of cataract after exposure to low doses of ionizing radiation: a 20-year prospective cohort study among US radiologic technologists.

Bruce H Alexander, Steven L Simon, Michael Hauptmann, 2008, American journal of epidemiology.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

M. Schiffman, P. Castle, T. Lorey, 2019, JAMA oncology.

Mixture models for undiagnosed prevalent disease and interval‐censored incident disease: applications to a cohort assembled from electronic health records

M. Schiffman, P. Castle, T. Lorey, 2017, Statistics in medicine.

Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening

A. Jemal, C. Berg, E. Jacobs, 2018, Annals of Internal Medicine.

Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap Cotesting in Posttreatment Management

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral‐host interaction with implications for disease intervention

M. Yeager, Kai Yu, L. Burdett, 2020, International journal of cancer.

Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

M. Schiffman, P. Castle, T. Lorey, 2014, Journal of the National Cancer Institute.

Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

Stephanie A Kovalchik, Hormuzd A Katki, C. Berg, 2016, JAMA.

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program

J. Cuzick, C. Wheeler, M. Schiffman, 2015, Cancer Epidemiology, Biomarkers & Prevention.

A cohort study of cervical screening using partial HPV typing and cytology triage

M. Schiffman, P. Castle, T. Raine-Bennett, 2016, International journal of cancer.

Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Using Prediction-Models to Reduce Persistent Racial/Ethnic Disparities in Draft 2020 USPSTF Lung-Cancer Screening Guidelines.

C. Berg, A. Chaturvedi, H. Katki, 2021, Journal of the National Cancer Institute.

The low risk of precancer after a screening result of human papillomavirus‐negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management

J. Cuzick, M. Schiffman, P. Castle, 2014, Cancer cytopathology.

Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Recalibration of a Deep Learning Model for Low-Dose Computed Tomographic Images to Inform Lung Cancer Screening Intervals

P. Pinsky, P. Castle, H. Katki, 2023, JAMA network open.

Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result.

C. Berg, A. Chaturvedi, H. Katki, 2019, Journal of the National Cancer Institute.

Basing eligibility for lung cancer screening on individualized risk calculators should save more lives, but life-expectancy matters.

H. Katki, R. Landy, L. Cheung, 2019, Journal of the National Cancer Institute.

Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol.

C. Berg, P. Brennan, H. Katki, 2019, The Lancet. Respiratory medicine.

Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.

C. Berg, A. Chaturvedi, H. Katki, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.

T. Beaty, S. de Sanjosé, R. Nayar, 2023, Gynecologic oncology.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

M. Schiffman, P. Castle, T. Lorey, 2018, Preventive medicine.

Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage

L. R. Long, Kanan T. Desai, M. Schiffman, 2020, Infectious agents and cancer.

A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines

M. Schiffman, N. Wentzensen, P. Castle, 2020, Journal of lower genital tract disease.

Age‐stratified 5‐year risks of cervical precancer among women with enrollment and newly detected HPV infection

M. Schiffman, P. Castle, T. Lorey, 2015, International journal of cancer.

Low risk of type‐specific carcinogenic HPV re‐appearance with subsequent cervical intraepithelial neoplasia grade 2/3

S. Wacholder, D. Solomon, R. Burk, 2012, International journal of cancer.

Long‐term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment

M. Sherman, R. Burk, A. Hildesheim, 2012, International journal of cancer.

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting

M. Schiffman, P. Castle, T. Lorey, 2019, International journal of cancer.

Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

M. Schiffman, P. Castle, T. Lorey, 2018, Journal of the National Cancer Institute.

Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years

M. Schiffman, P. Castle, T. Raine-Bennett, 2013, Journal of lower genital tract disease.

Use of risk-based cervical screening programs in resource-limited settings.

Jayashree Kalpathy-Cramer, S. de Sanjosé, A. Rodriguez, 2023, Cancer epidemiology.

Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus–Positive Screening Test Results

Kanan T. Desai, Xin He, M. Schiffman, 2022, Journal of lower genital tract disease.

Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study

B. Graubard, A. Chaturvedi, H. Katki, 2023, Journal of the National Cancer Institute.

A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15‐year cervical cancer screening experience at Kaiser Permanente Northern California

M. Schiffman, P. Castle, T. Lorey, 2020, International journal of cancer.

Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility

Thomas J. Reese, Polina V. Kukhareva, D. Wetter, 2022, J. Am. Medical Informatics Assoc..

Five-year prospective evaluation of cytology, HPV testing, and biomarkers for detection of anal precancer in HIV+ MSM.

P. Castle, T. Lorey, R. Landy, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prioritized concordance index for hierarchical survival outcomes

H. Katki, L. Cheung, Li C. Cheung, 2019, Statistics in medicine.

Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever‐Smokers for Lung Cancer Screening

N. Freedman, H. Katki, N. Caporaso, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-year prospective evaluation of cytology, HPV testing, and biomarkers for detection of anal precancer in HIV+ MSM.

P. Castle, T. Lorey, R. Landy, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A modeling analysis to compare eligibility strategies for lung cancer screening in Brazil

F. Bray, A. Carvalho, M. Johansson, 2021, EClinicalMedicine.

Methods for Using Race and Ethnicity in Prediction Models for Lung Cancer Screening Eligibility

H. Katki, T. Caverly, L. Cheung, 2023, JAMA network open.

Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.

H. Katki, L. Cheung, Rebecca Landy, 2023, Cancer.

Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.

P. Castle, T. Lorey, N. Wentzensen, 2024, Gynecologic oncology.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

S. Wacholder, M. Schiffman, P. Castle, 2011, The Lancet. Oncology.